Top 50 Life Science VC Funds & Investors in Europe (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
20 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Sofinnova Partners
VC Fund
|
19 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$102M |
|
Parkwalk Advisors
VC Fund
|
17 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $982k–$46M |
|
Bpifrance
VC Fund
|
16 | France, United States, Switzerland | Seed, Series A | Software, Information Technology, Health Care | $658k–$35M |
|
Oxford Science Enterprises
VC Fund
|
14 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.3M–$168M |
|
UK Innovation & Science Seed Fund
VC Fund
|
14 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $393k–$14M |
|
Kurma Partners
VC Fund
|
11 | France, Switzerland, Spain | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $2.3M–$80M |
|
Development Bank of Wales
VC Fund
|
10 | United Kingdom, Australia, United States | Seed, Debt Financing | Software, Health Care, Biotechnology | $18k–$3.7M |
|
Novo Holdings
VC Fund
|
10 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $8M–$125M |
|
Seventure Partners
VC Fund
|
9 | France, United States, Germany | Series A, Series B | Biotechnology, Software, Health Care | $3.1M–$65M |
|
Centre for the Development of Industrial Technology (CDTI)
VC Fund
|
8 | Spain, United States, France | Grant, Seed | Biotechnology, Health Care, Software | $126k–$5.9M |
|
APEX Ventures
VC Fund
|
7 | Germany, United Kingdom, Austria | Seed, Series A, Pre-Seed | Artificial Intelligence, Software, Health Care | $511k–$21M |
|
Bullnet Capital
VC Fund
|
7 | Spain, United States, Mexico | Seed, Series A | Software, Information Technology, Manufacturing | $590k–$11M |
|
GM&C Life Sciences Fund
VC Fund
|
7 | United Kingdom, Italy, Germany | Seed, Series A | Health Care, Biotechnology, Medical | $65k–$4.1M |
|
Meusinvest (Noshaq)
VC Fund
|
7 | Belgium, France, Germany | Series A, Seed | Biotechnology, Health Care, Medical | $137k–$16M |
|
24 Haymarket
VC Fund
|
7 | United Kingdom, United States | Seed, Series A | Health Care, Software, Information Technology | $714k–$16M |
|
Nina Capital
VC Fund
|
7 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $573k–$22M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
7 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $909k–$33M |
|
Syncona Partners LLP
VC Fund
|
7 | United Kingdom, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.8M–$131M |
|
IQ Capital
VC Fund
|
7 | United Kingdom, United States, Germany | Seed, Series A | Software, Artificial Intelligence, Machine Learning | $1.3M–$19M |
|
Scottish Enterprise
VC Fund
|
7 | United Kingdom, United States, Japan | Seed, Grant | Biotechnology, Software, Health Care | $104k–$4.1M |
|
Idinvest Partners
VC Fund
|
6 | France, United States, Spain | Series B, Series A | Biotechnology, Health Care, Software | $3.3M–$66M |
|
Kindred Capital
VC Fund
|
6 | United Kingdom, United States, Germany | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1.5M–$73M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
6 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.3M–$50M |
|
Future Planet Capital
VC Fund
|
6 | United Kingdom, United States, Canada | Seed, Convertible Note | Biotechnology, Health Care, Software | $897k–$7.9M |
|
Archangels
VC Fund
|
6 | United Kingdom, United States | Seed, Series A | Software, Biotechnology, Health Care | $1.3M–$8.3M |
|
Angels in MedCity
VC Fund
|
6 | United Kingdom, United States | Seed, Angel | Health Care, Biotechnology, Medical | $458k–$880k |
|
Omnes Capital
VC Fund
|
6 | France, Germany, United States | Series A, Series B | Software, Biotechnology, Health Care | $3.5M–$43M |
|
Selvedge Venture
VC Fund
|
6 | United Kingdom, Singapore | Seed, Pre-Seed, Series A | Health Care, Biotechnology, Life Science | $1.1M–$30M |
|
Newable Private Investing
VC Fund
|
6 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $196k–$5.2M |
|
Capital Cell
VC Fund
|
6 | Spain, United States, United Kingdom | Equity Crowdfunding, Seed | Health Care, Biotechnology, Medical | $137k–$1.9M |
|
Amino Collective
VC Fund
|
6 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Medical | $125k–$26M |
|
Advent Life Sciences
VC Fund
|
5 | United States, United Kingdom, France | Series A, Series B | Biotechnology, Health Care, Medical | $5.5M–$75M |
|
Scottish Investment Bank
VC Fund
|
5 | United Kingdom, United States, France | Seed, Series A | Software, Biotechnology, Health Care | $327k–$7M |
|
Deepbridge Capital
VC Fund
|
5 | United Kingdom, Australia, Singapore | Seed, Series A | Health Care, Biotechnology, Medical | $152k–$15M |
|
Amadeus Capital Partners
VC Fund
|
5 | United Kingdom, United States, Spain | Series B, Seed, Series A | Software, Artificial Intelligence, Information Technology | $800k–$43M |
|
Voima Ventures
VC Fund
|
5 | Finland, Sweden, Norway | Seed, Pre-Seed, Series A | Biotechnology, Health Care, Artificial Intelligence | $439k–$18M |
|
R42 Group
VC Fund
|
5 | United Kingdom, United States, Austria | Seed, Pre-Seed | Biotechnology, Health Care, Software | $439k–$4M |
|
Enterprise Ireland
VC Fund
|
5 | Ireland, United States, United Kingdom | Seed, Series A | Software, Information Technology, Health Care | $439k–$12M |
|
PMV
VC Fund
|
5 | Belgium, United States, The Netherlands | Series A, Seed | Software, Biotechnology, Health Care | $549k–$40M |
|
Inventure
VC Fund
|
5 | Finland, Sweden, United States | Seed, Series A, Series B | Software, Information Technology, Health Care | $549k–$23M |
|
European Investment Bank
VC Fund
|
5 | Germany, France, The Netherlands | Debt Financing, Post-IPO Debt | Biotechnology, Health Care, Energy | |
|
IFB Innovationsstarter
VC Fund
|
5 | Germany, United States | Seed, Grant | Software, SaaS, Artificial Intelligence | $80k–$3M |
|
Epidarex Capital
VC Fund
|
5 | United Kingdom, United States, Germany | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $531k–$55M |
|
coparion
VC Fund
|
5 | Germany, Switzerland, United States | Series A, Seed, Series B | Software, SaaS, FinTech | |
|
Google Ventures
VC Fund
|
5 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1M–$105M |
|
AIB Seed Capital Fund
VC Fund
|
4 | Ireland, United States, Jersey | Seed, Series A | Software, Health Care, Medical | |
|
11.2 Capital
VC Fund
|
4 | United States, Canada, United Kingdom | Seed, Series A, Series B | Software, Information Technology, Biotechnology | |
|
Verve Ventures
VC Fund
|
4 | Switzerland, France, Germany | Series A, Seed, Series B | Health Care, Software, Biotechnology | |
|
IP Group
VC Fund
|
4 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Information Technology | |
| Access all 50 VC funds in Europe Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 298
- Round size: Series A $6M–$65M; Series B $10M–$102M; Series C $11M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- protera — Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed.Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.
- Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 255
- Round size: Seed $982k–$4.7M; Series A $1.6M–$13M; Series B $2M–$46M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Nozzle.ai — Award-winning Amazon analytics tools designed to provide FBA Amazon Sellers with unique customer insights. Try for Free.
- Phasecraft — Using disruptive theory to unlock the power of quantum computing
- Echion Technologies — Echion Technologies is a spinout from the University of Cambridge Engineering Department, using proprietary battery active materials to develop next-generation Li-ion batteries.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 988
- Round size: Seed $658k–$6.4M; Series A $2.5M–$35M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- May Health — May Health is developing a modern treatment - Ovarian Rebalancing - designed to restore ovulation for people with polycystic ovary syndrome.
- Callyope — Callyope is building the first speech-based foundational model to monitor mental health symptoms through low-touch smartphone interactions.
- Smile Wanted Group — Spot the most valuable inventory on premium websites and provide guarantees of performance to advertisers. Reach +500M users /month globally.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 161
- Round size: Seed $1.3M–$10M; Series A $5M–$46M; Series B $8.5M–$168M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $327M in 2022
Portfolio highlights
- Mode Labs — Mode Labs provide robust, continuous, and remote real-time chemical sensors.
- Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
- Pepgen — PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 130
- Round size: Seed $393k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
- Presymptom Health — Enabling Early Diagnosis for better infection & sepsis care. With faster, more accurate testing. Presymptom Health is a medtech company developing a portfolio of patented diagnostic tests that are both faster and more reliable than those available today. Accelerate diagnosis. Address antimicrobial resistance.
- Pencil Biosciences — Pencil Biosciences is pioneering the next generation of gene editing. We are developing a fully synthetic, RNA-guided platform designed to overcome the limitations of current technologies.
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, Spain
Investor stats
- Total investments: 128
- Round size: Seed $2.3M–$13M; Series A $3.8M–$74M; Series B $8.8M–$80M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Medlumics — Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.
- Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 211
- Round size: Seed $327k–$3.7M; Debt Financing $18k–$2M
- Lead/follow: 58% lead, 42% follow
- Last fund: May invest from a new fund soon — raised $25M in 2018
Portfolio highlights
- Forth — Forth are a group of clinical and digital experts who are passionate about healthcare. They’re part of a new breed of digital healthcare companies who are transforming people’s relationship with their health by using technology to give them more information and help them gain greater control.
- enModus — Experience the thrill of competing against other players in online casino tournaments! These events offer a unique opportunity to showcase your skills and
- Antiverse — Designing biologics for 100 challenging targets
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 313
- Round size: Series A $8M–$100M; Series B $12M–$125M; Series C $30M–$115M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Hillstar Bio — Hillstar Bio is pioneering precision immunotherapies that target and deplete pathogenic immune cells, aiming to reset the immune system and transform treatment for autoimmune diseases.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- Bolt Biotherapeutics — Bolt is leveraging the immune system for a better way to treat cancer. Our approach works with a person's body, not against it.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 213
- Round size: Series A $3.1M–$24M; Series B $3.3M–$65M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
- Karmen — Karmen offers revenue-based financial solutions such as venture capital and loans to accelerate business growth for SaaS companies.
- Flexvelop — Flexvelop combines financial technology with circular economy to add innovative values to the core function of equipment funding.Local vendors and online-shops integrate Flexvelop as a seamless embedded payment option. Business customers are now able to #flex new equipment per click right at the point of sale. Insurance is already covered, andour customers have now the weekly option, to buy- or return their equipment, easily. This enables a new world of worry-free and flexible business growth.We #flex business equipment from €300 up to €20.000 per item; e.g. coffee-machines, laptops, gym- or dental-equipment,... anything you need for your business.NEXT GENERATION PAYMENTS + Technological Innovation: fully automatic embedded payment option + Economical Innovation: optionality (rent/buy/return) + insurance included + Ecological Innovation: sustainability (contributing to a circular economy) = Enabling worry-free flexible business developmentForget renting. Forget leasing. Grow smart - flex it!
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Grant, Seed
- Geography: Spain, United States, France
Investor stats
- Total investments: 175
- Round size: Seed $562k–$5.9M; Grant $126k–$861k
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- Xoople — Xoople operates as an earth intelligence company. Xoople powers the next generation of Earth data intelligence to achieve a systematic understanding of physical changes on the Earth’s surface.
- TetraxAI — TetraxAI helps renewable energy developers and investors automate due diligence and risk assessment - 100x faster, 10x cheaper, with full legal traceability.
- Golden Owl —
APEX Ventures is a deep-tech and medical-focused venture capital firm.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United Kingdom, Austria
Investor stats
- Total investments: 53
- Round size: Seed $1.3M–$8M; Pre-Seed $511k–$3M; Series A $2.2M–$21M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- GEMESYS — Gemesys creates a chip that functions similarly to the human brain in order to overcome processing constraints and empower AI with the hardware it needs to complete its destiny
- HyperHeat — HyperHeat is building a cutting-edge, all-electric heating solution designed to reach temperatures of up to 2,000°C. Using renewable electricity HyperHeat is providing an efficient alternative to fossil fuel combustion. With an efficiency rate of up to 98%, HyperHeat is ideal for retrofitting industrial processes, enabling significant CO2reductions across industries like steel, cement, and chemicals. The scalable technology offers a cost-efficient approach to decarbonizing thermal processes, with a potential to reduce global CO2 emissions by over 4.5 gigatons annually.
- TriLite Technologies — The world's smallest projection displays from TriLite take laser beam scanning technology to the next level, for augmented vision as light as the eyewear of today.
Independent Venture Capital Firm specialized in high technology Spanish start-ups. Helping tech entrepreneurs during the early stages of their company to build successful businesses
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Seed, Series A
- Geography: Spain, United States, Mexico
Investor stats
- Total investments: 60
- Round size: Seed $1M–$3.3M; Series A $590k–$11M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $47M in 2023
Portfolio highlights
- FlexiiC — FlexiiC is a deep-tech firm developing printed, flexible integrated circuits for sustainable IoT and smart packaging solutions.
- Bioherent — Photonic biosensors for drug allergy diagnosis
- Impetux Optics — IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues and cells. We are focusing the application of our technology in fields like Mechanobiology where the study of diseases directly related with cell migration or development are demanding new techniques. We offer cutting-edge non-invasive to...
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Italy, Germany
Investor stats
- Total investments: 33
- Round size: Seed $65k–$936k; Series A $1.8M–$4.1M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Maxwellia — A contraceptive pill, Lovima, is now available to buy without a prescription.
- Acea Health — Acea Health is a digital healthcare company developing an application called Flynotes - a new digital consent platform. Flynotes analyses a number of factors, including the patient’s background, to deliver personalised risks and benefits. Flynotes aims to be the go-to solution for consent in healthcare. .
- Nexus Labs (Surgical Teaching) — Nexus Labs is an interactive learning resource for medical students.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 76
- Round size: Seed $137k–$6M; Series A $3.3M–$16M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 100
- Round size: Seed $714k–$3.8M; Series A $1.6M–$16M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Angoka — ANGOKA is an IoT security company focused on protecting M2M communications for Smart Cities and Mobility. Headquartered in Belfast, with offices in London and The Hague, ANGOKA offers solutions that protect devices’ identities. With an increase of inherently insecure networks coming online with the boom of IoT, ANGOKA’s solutions safeguard criticalmachine-to-machine communication integrity and data provenance, creating trusted connections, even in untrustworthy networks.ANGOKA is the only cybersecurity company to win a place on Zenzic’s CAM Scale-Up Programme, delivered in partnership with Plug and Play. ANGOKA was also the first NI start-up to be selected for NCSC’s Cyber Accelerator, who reviewed and assessed ANGOKA’s technology. ANGOKA is also an alumnus of Seraphim Space Camp, Yes!Delft and TechNation Cyber 2.0. Finally, ANGOKA has been awarded several Innovate UK R&D projects, which focus on securing quantum communications (led by BT) and two drone projects.
- CyberOwl — CyberOwl develops an innovative early warning system for attacks through real-time monitoring of high-value targets for malicious behavior. The technology, based on research shortlisted for the Lloyd’s Science of Risk Prize 2015, is aimed at addressing the challenges of increasingly anonymous and persistent threats to rapidly-expanding globalnetworks, particularly in the wake of Smart Cities and the Internet of Things. The system raises early warning on network assets for possible undesirable activity, by applying a Bayesian-based framework to systematically analyze indicators associated with early stages of such activity. This approach dramatically reduces the processing overheads of monitoring. The benefits to the security operation include scalability to networks exceeding 1 billion devices, providing earlier visibility of risk and improving prioritization and decision-making in deploying countermeasures. CyberOwl is developing its minimum viable product and is looking for two or three strategic industry design partners for validation, verification, and further development. The ideal design partner would provide access to real-world security problems in a large network, high-volume data environment.CyberOwl was founded on 2016 and is headquartered in London, England.
- Kelda Technology — Kelda Technology is a British clean tech business that develops water-in-air shower products that halve water usage and water heating costs through patented shower technology. Kelda Technology has adapted cutting edge automotive and aerospace technology to produce a revolutionary “water-in-air” shower system that halves water use without any lossin performance. Water is broken into droplets to form a comfortable spray which is accelerated using a globally patented jet-type nozzle. Not only does it halve water costs, but also halves associated heating costs.The Kelda shower system holds appeal for a wide range of sectors, including gym and leisure, hotels and accommodation providers, healthcare, and maritime – all industries where water efficiency is key. The product has completed in-market validation and commercial trials, is in manufacture and the company has already signed installation deals with some of the largest leisure operators in the UK and Latin America.Kelda Technology was recently chosen as one of the top 30 cleantech companies in the world at the New Energy Start-Up awards 2016 and was this week shortlisted by the UK Business Angels Association for Best Investment in a Disruptive Tech Business.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 81
- Round size: Seed $2M–$5.2M; Pre-Seed $573k–$2.4M; Series A $5M–$22M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- io Health — Io Health Technologies LLC provides AI-driven tools for home health documentation and workflow automation in healthcare.
- Sober Sidekick — Gamified peer to peer support
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 542
- Round size: Seed $909k–$6.5M; Series A $3M–$33M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- Sdui — Sdui is the solution for mobile communication in schools. With amazingly easy features for messaging, timetables and a wide range of third party integrations, the app digitizes processes and reduces administrative effort. Within two years, Sdui has reached hundreds of institutions and grown a serious reputation in the educational market.
- envelio — We are driving forward the energy transition with our smart grid solutions for grid operators. Get information now and plan smart!
- Atriva Therapeutics — Therapies against viral infections. First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 50
- Round size: Seed $1.8M–$17M; Series A $17M–$110M; Series B $24M–$131M
- Lead/follow: 58% lead, 42% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Apini Therapeutics — Apini is a creating novel small chemical two most prevalent types of inflammatory bowel disease.
- Purespring Therapeutics — A precision nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function.
IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 183
- Round size: Seed $1.3M–$12M; Series A $4.5M–$19M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Molyon — Molyon is creating the next-generation energy storage system: the lithium-sulfer battery. Molyon offers long-life lithium-sulfur batteries that have twice the energy density of existing lithium-ion batteries on the market.
- Nyobolt — Nyobolt develops high-power energy storage systems based on advanced lithium-ion battery technology designed for rapid charging and sustained high performance. The company focuses on battery systems that enable very fast energy replenishment, supporting applications where downtime needs to be minimized. Its technology combines specialized anodematerials, cell design, battery management systems, and power electronics to achieve high charge and discharge rates. The platform is used in sectors such as robotics, data centers, industrial equipment, and electric mobility where consistent high power delivery is required. It also develops integrated energy solutions that support demanding workloads like automated logistics systems and high-performance computing infrastructure. Nyobolt’s approach emphasizes optimizing cycle life, thermal stability, and energy density for repeated fast charging environments.
- AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Grant
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 285
- Round size: Seed $300k–$3.4M; Grant $104k–$4.1M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- TileBio —
- Sentinel —
- Orbital Marine Power — Orbital Marine Power is an innovative Scottish engineering company focused on the development of a low-cost, predictable, scalable floating tidal technology.
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series A
- Geography: France, United States, Spain
Investor stats
- Total investments: 252
- Round size: Series A $3.3M–$24M; Series B $7.8M–$66M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $88M in 2021
Portfolio highlights
- Ornikar — Ornikar is an online driving school that offers radically cheaper, uncomplicated and faster offer to obtain a driving license.Ornikar relies on a network of state-qualified teachers to offer an apprenticeship in mobile driving at reduced prices. The cmpany is an an online driving school more in tune with the demand of current and futuregenerations.The company's mission is to make the driver's license exam cheaper and its learning more enjoyable.
- Glovo — Glovo delivers the best products of your city in less than 1 hour
- Stanley Robotics — Stanley Robotics is a DeepTech business helping the transportation and logistics industries digitalise and robotise outdoor operations.
A new model for Venture Capital where every founder we back becomes a co-owner of the fund
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 108
- Round size: Seed $1.5M–$16M; Series A $7.9M–$33M; Series B $13M–$73M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Hofy — Use Hofy's equipment management platform to remotely supply, manage and maintain subscription workstations, while staying compliant.
- RobCo — Easily automate the repetitive tasks in your production facility with modular industrial robots from RobCo.
- Paddle — The revenue engine powering payments for n8n, Letterboxd & AdGuard. One platform that handles subscription billing, payments and compliance.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 94
- Round size: Seed $1.3M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
- Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 142
- Round size: Seed $897k–$7.9M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
- Vitarka Therapeutics — Vitarka Therapeutics has engineered an intracellular drug delivery technology, EndoPore, using pore forming proteins for intracellular targets.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 84
- Round size: Seed $1.3M–$2.9M; Series A $1.6M–$8.3M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- CSignum — Revolutionising underwater communications with electromagnetic technology for seamless data integration between surface & submerged devices.
- BioCaptiva — BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
- Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Angel
- Geography: United Kingdom, United States
Investor stats
- Total investments: 18
- Round size: Seed $458k–$880k
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
- DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.
Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B
- Geography: France, Germany, United States
Investor stats
- Total investments: 173
- Round size: Series A $3.5M–$37M; Series B $4.4M–$43M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $403M in 2020
Portfolio highlights
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
- Amakem — Easy, affordable options for you to obtain the domain you want. Safe and secure shopping.
- Lithosquare — Lithosquare is a mining company that specializes in the extraction of non-ferrous metal ores.
Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, Singapore
Investor stats
- Total investments: 13
- Round size: Seed $1.4M–$9.6M; Pre-Seed $1.1M–$2.5M; Series A $3.5M–$30M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
- BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.
- Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 103
- Round size: Seed $196k–$3.9M; Series A $1.3M–$5.2M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- Elemendar — Elemendar is building Artificial Intelligence that reads cyber threat reports by humans and turns them into industry-standard structured information.
- NuVision — NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Capital Cell is a crowdinvesting platform for biotech and life sciences companies. Mixing VC, business angels, accredited investors, and the power of the crowd, the company is building a global meeting point for companies and researchers working, fostering, and financing tomorrow’s medical science.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Equity Crowdfunding, Seed
- Geography: Spain, United States, United Kingdom
Investor stats
- Total investments: 49
- Round size: Seed $384k–$1.9M; Equity Crowdfunding $137k–$1.3M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- MgShell — MgShell offers intraocular devices for the treatment of age-related macular degeneration and other ocular diseases. Their technology is the only technical solution capable of replicating current clinical practice with a single injection and releasing the same therapeutic drug doses at predetermined periods, autonomously and without surgicalprocedures.
- DYNAMICS VR — Dynamics VR provides rehab software for clinics to tackle musculoskeletal pain and movement impairments caused by brain trauma.
- EVis Bioscience — EVis Bioscience offers gene delivery solutions using extracellular vesicles, lipid nanoparticles, and hybrid systems.
Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 40
- Round size: Seed $2.4M–$15M; Pre-Seed $125k–$7.8M; Series A $12M–$26M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Lindus — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
- Nostos Genomics — Our genetic variant interpretation platform enables genetic testing labs to give more people with genetic diseases a clear and fast diagnosis.
- Kernal Biologics — Kernal biologics is an onco-selective mRNA therapeutics company located in Cambridge, MA
Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 64
- Round size: Series A $5.5M–$53M; Series B $21M–$75M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- MiroBio — MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control.
- Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
- Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.
Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 208
- Round size: Seed $327k–$3.1M; Series A $1.6M–$7M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
- Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Australia, Singapore
Investor stats
- Total investments: 82
- Round size: Seed $152k–$2.6M; Series A $2M–$15M
- Lead/follow: 74% lead, 26% follow
- Last fund: Likely still investing — raised $1.4M in 2022
Portfolio highlights
- upLYFT — upLYFT is working on the next generation of smart wearables to help with musculoskeletal issues related to aging. Also working with pro athletes to help sporting individuals train harder and break records.
- GeneralPractice.AI — General Practice. AI is an advanced, AI-powered platform designed to transform primary care and general practice by streamlining clinical workflows, enhancing patient engagement, and reducing administrative burdens for healthcare professionals. It aims to revolutionize primary care by harnessing artificial intelligence to improve both clinical andadministrative aspects of general practice, ultimately delivering more efficient, personalized, and effective healthcare.
- Spotlight Pathology — Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers.
Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series B, Seed, Series A
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 230
- Round size: Seed $800k–$9.2M; Series A $2.6M–$27M; Series B $6.8M–$43M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $88M in 2023
Portfolio highlights
- Tenzo — Tenzo is a restaurant analytics and AI forecasting platform for restaurants, pubs and cafes. Tenzo makes running restaurants easy with full data visibility.
- Xampla — Xampla's natural plant polymer technology is the innovative technology powering materials to change the world with plastic-free replacements and more.
- Nu Quantum — Nu Quantum has been pioneering quantum networking technology since 2018. Our market-leading expertise is uniquely positioned to deliver a distributed quantum...
Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: Finland, Sweden, Norway
Investor stats
- Total investments: 59
- Round size: Seed $1M–$5.5M; Pre-Seed $439k–$2.1M; Series A $3.8M–$18M
- Lead/follow: 64% lead, 36% follow
Portfolio highlights
- MVision AI — AI-powered solutions that automate repetitive tasks, enable efficient radiotherapy workflows, and promote consistency across clinical processes.
- Quantrol Ox — Building Machine Learning Based Software for Quantum Control with a goal to maximise quantum computer uptime.
- Adamant Health — Adamant Health’s unique technology to analyse Parkinson’s disease symptoms is based on over 15 years of academic research at the University of Eastern Finland. With the technology, clinicians have several days detailed visibility to the patient’s symptoms and is able to optimise the treatment accordingly. Pharma companies benefit from the objectiveand long-term RW data in their clinical and post market studies and can utilise it as complementary diagnostics tool for personalised medication.
R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, Austria
Investor stats
- Total investments: 27
- Round size: Seed $654k–$4M; Pre-Seed $439k–$2M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
- xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
- Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.
Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 485
- Round size: Seed $439k–$3.3M; Series A $2.2M–$12M
- Lead/follow: 19% lead, 81% follow
- Last fund: May invest from a new fund soon — raised $1.1M in 2021
Portfolio highlights
- Tirlan — Tirlan is an agricultural company that supplies agri-food and farm input materials to the framing sector.
- Lakeland Dairies — Lakeland Dairies, a major dairy processing co-operative, operates within a fifteen county catchment area across the northern half of the island of Ireland. The Group processes about one billion litres of quality milk annually into a range of value added dairy foodservice products and functional dairy food ingredients.
- Touchtech Payments — At Touchtech Payments, believe in making industry changing and innovative technology.
Do and dare company
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Seed
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 138
- Round size: Seed $549k–$3.8M; Series A $2.7M–$40M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- LindaCare — LindaCare develops solutions for implantable cardiac device remote monitoring. From intuitive dashboards for caregivers to managed remote monitoring service, LindaCare is at the forefront of the monitoring revolution.
- Gorilla — We empower Energy Retailers in pricing, forecasting and reporting with data-driven solutions in boosting speed and flexibility.
- Predikt — Predikt empowers finance leaders to navigate today’s volatile markets with clarity and confidence. By integrating advanced AI, external market data, and internal financial metrics, Predikt transforms forecasting into a strategic advantage.Our pioneering Confidence Intelligence platform:- Provides transparency and automation to reduceforecasting uncertainty. - Enables CFOs to assess risks, identify opportunities, and align teams globally. - Turns data into decisions that foster resilience and drive growth.We understand the challenges finance leaders face: juggling a high-level view with local market complexities. That’s why Predikt is designed to enhance collaboration, challenge assumptions, and provide confidence in every number.Founded by a Swiss-Belgian team in 2023, Predikt is democratizing predictive technology, equipping finance teams to make smarter decisions and thrive amid uncertainty.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Finland, Sweden, United States
Investor stats
- Total investments: 164
- Round size: Seed $549k–$6M; Series A $1.3M–$17M; Series B $1.3M–$23M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $169M in 2022
Portfolio highlights
- Omocom — Omocom offers safe, simple and secure insurance for all kind of renting, sharing and re-using, digitally, automated and integrated into the sales flow of the platform
- Moncyte Health — Unique technology and novel data for personalized and optimal treatment of high cholesterol
- Blueprint Genetics — We offer complete genetic testing and genetic diagnostics to medical professionals worldwide. Learn more about our winning clinical-grade NGS offering!
The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Energy
- Stage:Debt Financing, Post-IPO Debt
- Geography: Germany, France, The Netherlands
Investor stats
- Total investments: 247
- Lead/follow: no public data
Portfolio highlights
- Amadix — Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide.The most advancedproduct developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
- Greenlight Biosciences — Next Generation Crop Protection
- Azienda Comprensoriale Acquedottistica — ACA Spa is an integrated water service company.
The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.
Show more...Investment focus
- Industry: Software, SaaS, Artificial Intelligence
- Stage:Seed, Grant
- Geography: Germany, United States
Investor stats
- Total investments: 77
- Round size: Seed $658k–$3M; Grant $80k–$165k
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- mo:re GmbH — We offer standardized tissue cultures and protocols to better predict drug responses and investigate disease models.
- Flexvelop — Flexvelop combines financial technology with circular economy to add innovative values to the core function of equipment funding.Local vendors and online-shops integrate Flexvelop as a seamless embedded payment option. Business customers are now able to #flex new equipment per click right at the point of sale. Insurance is already covered, andour customers have now the weekly option, to buy- or return their equipment, easily. This enables a new world of worry-free and flexible business growth.We #flex business equipment from €300 up to €20.000 per item; e.g. coffee-machines, laptops, gym- or dental-equipment,... anything you need for your business.NEXT GENERATION PAYMENTS + Technological Innovation: fully automatic embedded payment option + Economical Innovation: optionality (rent/buy/return) + insurance included + Ecological Innovation: sustainability (contributing to a circular economy) = Enabling worry-free flexible business developmentForget renting. Forget leasing. Grow smart - flex it!
- eleQtron — eleQtron creates and operates quantum computers based on trapped ions, radio frequency control, and Magnetic Gradient Induced Coupling (MAGIC). It also puts forward novel ideas for scalable quantum processors based on RF-controlled trapped ions. eleQtron will run MAGIC quantum computers and provide quantum computing performance on a subscriptionbasis.
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 47
- Round size: Seed $531k–$8.5M; Series A $2.6M–$40M; Series B $2.4M–$55M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Leucid Bio — CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
- Ryme Medical — Ryme Medical is a device company developing a novel catheter-based treatment for COPD
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.
Show more...Investment focus
- Industry: Software, SaaS, FinTech
- Stage:Series A, Seed, Series B
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 97
- Lead/follow: no public data
Portfolio highlights
- Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
- Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 983
- Round size: Seed $1M–$13M; Series A $5.4M–$86M; Series B $15M–$105M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- Allara — Allara is your all-in-one virtual care team for hormonal, metabolic & gynecological conditions such as PCOS and Endometriosis.
- Smarterer — Individuals and Fortune 500 companies use Smarterer to help close the gap between the skills they have and the skills they need. Their dynamic assessment engine leverages the freshest crowdsourced tests around, to rapidly pinpoint skill level with a credible score. In November 2014, Pluralsight, the global leader in online learning for serioussoftware developers, IT specialists and creative technologists, acquired Smarterer. As the world's largest curated e-learning library for professionals, the company offers instant access to more than 3,500 courses authored by top experts. Smarterer will continue to power crowdsourced assessments for freelancer marketplaces, e-learning providers and enterprise companies anywhere people need to prove their skills to connect with professional opportunities. The Smarterer community has answered over 56 million during 1.7 million test sessions, across hundreds of tests.
- Merida Biosciences — Merida Biosciences is a new biotech company focused on developing precision treatments, particularly for autoimmune diseases. The company utilize a protein engineering platform to create unique Fc therapeutics, aiming to selectively bind to specific antibodies.
The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012.The Fund has a total of €30m under managementwith AIB and Enterprise Ireland both committing €15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success.The Fund managers are empowered to make seed investments of up to approximately €500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies.The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise.Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of €250,000 from the fund within the city and county of Dublin.Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed €250,000.
Show more...Investment focus
- Industry: Software, Health Care, Medical
- Stage:Seed, Series A
- Geography: Ireland, United States, Jersey
Investor stats
- Total investments: 49
- Lead/follow: no public data
Portfolio highlights
- NewsWhip — The only real-time media monitoring platform that predicts the stories and topics that will matter in the hours ahead.
- Offr — Offr is the new way to buy and sell property, quickly and transparently.
- Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.
In physics, 11.2 km/s is the escape velocity from Earth's gravity. They focus on emerging technologies such as AI, cybersecurity, robotics, quantum, new space, computational therapeutics, synthetic biology. They believe great people are leading indicators of a company's success. 11.2 Capital’s technical background, operationalexperience, and a strong network of amazing advisors and international partners particularly in Asia deliver a unique set of resources to entrepreneurs. While they are happy to help companies across the full range of early-stage company questions, areas where they concentrate include technical recruiting, partnerships (OEM and distribution partnerships for smart hardware companies, data partnerships for data-driven healthcare companies), customer introductions (CISO introductions for security companies, provider introductions for healthcare companies), and follow-on financings.
Show more...Investment focus
- Industry: Software, Information Technology, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 57
- Lead/follow: no public data
Portfolio highlights
- HUMAN — HUMAN is a cybersecurity company that protects enterprises from bot attacks to keep digital experiences human.
- CryptoNumerics — HIPAA, GDPR and Data Residency requirements restrict your ability to conduct data science. CryptoNumerics removes these restrictions. CryptoNumerics enables you to create privacy protected datasets with quantifiable privacy risk. In addition, you can build statistical and machine learning models that protect people’s privacy. Our team consists ofengineers and visionaries with previous experience in C-Level roles at Fortune 500 companies, founding teams of venture backed growth stage start-ups, and accomplished R&D leaders.
- Coalesce Automation — Coalesce is the only data transformation tool built for scale. Evolve your transformations and empower your entire data team.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, France, Germany
Investor stats
- Total investments: 239
- Lead/follow: no public data
Portfolio highlights
- Q.ANT — Q.ANT develops photonic processors for AI and high-performance computing, utilizing light for information processing. The company also produces quantum sensors offering ultra-high magnetic field sensitivity in a compact form factor. These products aim to enable more intelligent and sustainable systems across various sectors like data centers,aerospace, and medical technology.
- Lexroom.ai — Lexroom.ai allows lawyers to complete hours of legal research in seconds.Legal professionals spend up to 50% of their time in repetitive, low value-adding tasks. That’s why we’re building Lexroom.ai, a product that allows lawyers to complete hours of research in seconds, so they can focus on what really matters.Lexroom.ai perfectly integrateswith lawyers' daily workflow and enables them to speed up time-consuming legal research tasks while increasing output quality, so that they can focus more on value-adding activities.Lexroom.ai is building a bridge between advanced artificial intelligence technologies and legal professionals, through a product specifically tailored to their needs.
- EarlySight — EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 179
- Lead/follow: no public data
Portfolio highlights
- Lumai — Lumai delivers fully optical computing for a quicker, smarter and more sustainable world. Lumai power the revolution of fully optical computing by working at the nexus of photonics and machine learning.
- Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
- Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science VC Funds in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 VC funds investing in Europe Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!